Brief: AC Immune Positive Interim Phase 2 Data On ACI-7104.056 Support Potential Slowing Of Progression Of Parkinson’s Disease
Dec 11 (Reuters) - AC Immune SA ACIU.O: AC IMMUNE POSITIVE INTERIM PHASE 2 DATA ON ACI-7104.056 SUPPORT POTENTIAL SLOWING OF PROGRESSION OF PARKINSON’S DISEASE AC IMMUNE SA - IMMUNOTHERAPY COULD SLOW PARKINSON'S PROGRESSION AC IMMUNE SA - ACI-7104.056 SHOWS CLEAR SAFETY PROFILE AC IMMUNE SA - TARGETS MET FOR IMMUNOGENICITY AND PHARMACODYNAMICS AC IMMUNE SA - ACI-7105.056 SAFE AND WELL-TOLERATED Source text: ID:nGNXc2FcSb Further company coverage: ACIU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture